Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Conference Call Scheduled for Thursday, February 28, 2019 at 8:30 a.m. ET
NEWTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, February 28, 2019 to discuss the financial results and recent business developments.
To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least 10 minutes prior to the start time and refer to conference ID 4246798. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has several investigational programs in clinical or preclinical development.
Karyopharm Therapeutics Inc.
Vice President, Investor and Public Relations
857-297-2241 | firstname.lastname@example.org
212-600-1902 | email@example.com
Source: Karyopharm Therapeutics Inc.